1. Show article details.

    HTG Molecular Diagnostics to Present Corporate Overview at Fall Investor Conferences

    GlobeNewswire – 4:01 PM ET 09/08/2020

    HTG Molecular Diagnostics, Inc. (HTGM), a diagnostic company whose mission is to advance precision medicine, today announced John Lubniewski, President and CEO of HTG, will present virtually at the H.C. Wainwright 22nd Annual Global Investment Conference and at the Cantor Fitzgerald Global Healthcare Conference. About HTG HTG is focused on NGS-based molecular profiling.

  2. Show article details.

    HTG Introduces Oncology Applications and Expands Analytics Capabilities with Release of New Software Update

    GlobeNewswire – 8:00 AM ET 08/18/2020

    HTG Molecular Diagnostics, Inc. (HTGM), a life science company whose mission is to advance precision medicine, today announced the commercial release and immediate availability of HTG EdgeSeq Reveal version 3.0, adding additional applications and software functionalities.

  3. Show article details.

    BRIEF-HTG Molecular Provides Update On Patent Infringement Claims Against Biospyder

    Reuters – 3:23 PM ET 08/14/2020

    HTG Molecular Diagnostics Inc (HTGM): * HTG MOLECULAR PROVIDES UPDATE ON PATENT INFRINGEMENT CLAIMS AGAINST BIOSPYDER. * HTG MOLECULAR DIAGNOSTICS (HTGM) - ON AUGUST 13, BIOSPYDER FILED A LAWSUIT SEEKING A DECLARATION THAT IT DOES NOT INFRINGE CO'S U.S. PATENT.

  4. Show article details.

    HTG Molecular Provides Update on Patent Infringement Claims Against BioSpyder

    GlobeNewswire – 2:17 PM ET 08/14/2020

    HTG Molecular Diagnostics, Inc. (HTGM), a life science company whose mission is to advance precision medicine, today provided an update regarding its patent infringement claims against BioSpyder Technologies, Inc. On August 13, 2020, BioSpyder filed a lawsuit seeking a declaration that it does not infringe HTG’s U.S. Patent No. 8,741,564.

  5. Show article details.

    BRIEF-HTG Molecular Diagnostics Reports Q2 Loss Per Share Of $0.09

    Reuters – 4:48 PM ET 08/11/2020

    HTG Molecular Diagnostics Inc (HTGM): * HTG MOLECULAR DIAGNOSTICS REPORTS SECOND QUARTER 2020 RESULTS. * Q2 LOSS PER SHARE $0.09. * Q2 REVENUE $2.0 MILLION VERSUS REFINITIV IBES ESTIMATE OF $1.8 MILLION. * Q2 EARNINGS PER SHARE ESTIMATE $-0.09 -- REFINITIV IBES DATA Source text for Eikon: Further company coverage:

  6. Show article details.

    HTG Molecular Diagnostics Reports Second Quarter 2020 Results

    GlobeNewswire – 4:01 PM ET 08/11/2020

    HTG Molecular Diagnostics, Inc. (HTGM), a life science company whose mission is to advance precision medicine, today reported its financial results for the quarter ended June 30, 2020.

  7. Show article details.

    BRIEF-HTG Molecular Diagnostics Announces New Commercialization And Distribution Agreement For Companion Diagnostics With Qiagen

    Reuters – 7:35 PM ET 08/10/2020

    HTG Molecular Diagnostics Inc (HTGM): * HTG MOLECULAR DIAGNOSTICS ANNOUNCES NEW COMMERCIALIZATION AND DISTRIBUTION AGREEMENT FOR COMPANION DIAGNOSTICS WITH QIAGEN. * HTG Molecular Diagnostics Inc (HTGM) - MASTER AGREEMENT ALLOWS HTG TO ENGAGE DIRECTLY WITH BIOPHARMA CUSTOMERS FOR CDX DEVELOPMENT PROGRAMS Source text for Eikon: Further company coverage:

  8. Show article details.

    HTG Molecular Diagnostics Announces New Commercialization and Distribution Agreement for Companion Diagnostics with QIAGEN

    GlobeNewswire – 4:01 PM ET 08/10/2020

    HTG Molecular Diagnostics, Inc. (HTGM), a life science company whose mission is to advance precision medicine, today announced the signing of a Commercialization and Distribution Agreement with QIAGEN Manchester Limited, a wholly owned subsidiary of QIAGEN N.V. (QGEN). The 10-year agreement provides a foundation for both companies to combine their technological and commercial strengths with the goal to offer...

  9. Show article details.

    HTG Molecular Diagnostics to Announce Second Quarter 2020 Financial Results and Host Conference Call on Tuesday, August 11

    GlobeNewswire – 4:01 PM ET 08/05/2020

    HTG Molecular Diagnostics, Inc. (HTGM), a diagnostic company whose mission is to advance precision medicine, today announced that it will report its financial results for the second quarter ended June 30, 2020 after the market close on Tuesday, August 11, 2020. About HTGHTG is focused on NGS-based molecular profiling.

  10. Show article details.

    HTG Introduces HTG EdgeSeq Reveal RUO Oncology Applications

    GlobeNewswire – 8:00 AM ET 08/04/2020

    HTG Molecular Diagnostics, Inc. (HTGM), a life science company whose mission is to advance precision medicine, today announced the pre-launch introduction of its new HTG EdgeSeq Reveal RUO oncology applications, which are expected to be commercially available globally in late August with the release of HTG EdgeSeq Reveal version 3.0. In January 2019, HTG launched HTG EdgeSeq Reveal, a web-based biosta...

  11. Show article details.

    HTG Expands RUO Profiling Menu with New NGS Platform Capability Assays

    GlobeNewswire – 4:01 PM ET 07/30/2020

    HTG Molecular Diagnostics, Inc. (HTGM), a life science company whose mission is to advance precision medicine, today announced three of its previously released Research Use Only assays are now available for use with the Thermo Fisher Scientific Ion Torrent Ion S5 next-generation sequencing platform.

  12. Show article details.

    HTG Launches New HTG EdgeSeq Pan B-Cell Lymphoma Panel

    GlobeNewswire – 4:05 PM ET 07/28/2020

    HTG Molecular Diagnostics, Inc. (HTGM), a life science company whose mission is to advance precision medicine, today announced the launch and immediate availability of the HTG EdgeSeq Pan B-Cell Lymphoma Panel in the United States and Europe.

  13. Show article details.

    HTG Announces Recipients of Its 2020 HTG EdgeSeq Autoimmune Panel Research Grants

    GlobeNewswire – 4:05 PM ET 07/23/2020

    HTG Molecular Diagnostics, Inc. (HTGM), a life science company whose mission is to advance precision medicine, today announced Vinodh Pillai, M.D., Ph.D., Assistant Professor of Pathology and Laboratory Medicine at the Children’s Hospital of Philadelphia, and Thomas Dörner, MD, Professor of Rheumatology and Hemostaseology at Charité University Hospitals, Berlin, as award recipients of its 2020 HTG Edg...

  14. Show article details.

    HTG Molecular Diagnostics Secures Senior Term Loan from Silicon Valley Bank

    GlobeNewswire – 4:01 PM ET 06/25/2020

    HTG Molecular Diagnostics, Inc. (HTGM), a life science company whose mission is to advance precision medicine, today announced that it has entered into a $10.0 million senior term loan agreement with Silicon Valley Bank, the bank of the world’s most innovative companies and their investors, to replace its existing senior credit facility.

  15. Show article details.

    HTG EdgeSeq Technology Highlighted in Multiple Posters Presented by Pharma Partners at the 2020 American Association for Cancer Research Virtual Meeting

    GlobeNewswire – 4:01 PM ET 06/23/2020

    HTG Molecular Diagnostics, Inc. (HTGM), a life science company whose mission is to advance precision medicine, today announced its HTG EdgeSeq technology was highlighted in multiple posters presented by global pharma company partners at the American Association for Cancer Research 2020 Virtual Meeting.

  16. Show article details.

    HTG Introduces the HTG EdgeSeq Pan B-Cell Lymphoma Panel

    GlobeNewswire – 4:01 PM ET 06/18/2020

    HTG Molecular Diagnostics, Inc. (HTGM), a life science company whose mission is to advance precision medicine, today announced the pre-launch introduction of its new HTG EdgeSeq Pan B-Cell Lymphoma Panel, which is expected to be commercially available for purchase in kit form or as a service in HTG’s VERI/O laboratory starting in July 2020.

  17. Show article details.

    HTG Adds Three New Distributors in Europe, Expanding and Strengthening Reach in the Nordics and Eastern Europe

    GlobeNewswire – 4:01 PM ET 06/11/2020

    HTG Molecular Diagnostics, Inc. (HTGM), a life science company whose mission is to advance precision medicine, today announced the signing of three new European distributor agreements to promote HTG products and services in Nordic and Eastern European Countries with BioNordika, Explorea, and ELTA 90.

  18. Show article details.

    HTG EdgeSeq Technology Highlighted in Several Posters at ASCO

    GlobeNewswire – 8:00 AM ET 06/02/2020

    HTG Molecular Diagnostics, Inc. (HTGM), a life science company whose mission is to advance precision medicine, today announced its HTG EdgeSeq technology was highlighted in several posters presented at the American Society of Clinical Oncology 2020 Virtual program.

  19. Show article details.

    HTG Molecular Diagnostics Reports First Quarter 2020 Results

    GlobeNewswire – 4:05 PM ET 05/13/2020

    HTG Molecular Diagnostics, Inc. (HTGM), a life science company whose mission is to advance precision medicine, today reported its financial results for the first quarter ended March 31, 2020. “With the COVID-19 pandemic impacting businesses globally, the first quarter of 2020 was unlike anything we would have anticipated.

  20. Show article details.

    HTG Molecular Diagnostics to Announce First Quarter 2020 Financial Results and Host Conference Call on Wednesday, May 13

    GlobeNewswire – 4:01 PM ET 05/11/2020

    HTG Molecular Diagnostics, Inc. (HTGM), a diagnostic company whose mission is to advance precision medicine, today announced that it will report its financial results for the first quarter ended March 31, 2020 after the market close on Wednesday, May 13, 2020. About HTG: HTG is focused on NGS-based molecular profiling.

Page:

Today's and Upcoming Events

  • Nov
    11

    HTGM to announce Q3 earnings (Unconfirmed)

Past Events (last 90 days)

  • Aug
    11

    HTGM announced Q2 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.